HLA genotype testing for carbamazepine, oxcarbazepine and eslicarbazepine: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI-PGx).

Galloway L, Dello Russo C, Bass N, Bramon E, Cross H, Curley N, Curran S, Davies H, De Villiers J, Evans W, Frank B, Groves A, Hayward J, Higham J, Hughes DA, Kyaw SS, Marson AG, McLellan A, Mensah S, O'Neill F, Sargison J, Sisodiya SM, Swan J, Zakrewska JM, Pirmohamed M.

Open source

DOI: 10.1002/bcp.70559
Published: 2026-04-19
Container: Br J Clin Pharmacol
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1002/bcp.70559,
  title = {HLA genotype testing for carbamazepine, oxcarbazepine and eslicarbazepine: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI-PGx).},
  author = {Galloway L and  Dello Russo C and  Bass N and  Bramon E and  Cross H and  Curley N and  Curran S and  Davies H and  De Villiers J and  Evans W and  Frank B and  Groves A and  Hayward J and  Higham J and  Hughes DA and  Kyaw SS and  Marson AG and  McLellan A and  Mensah S and  O'Neill F and  Sargison J and  Sisodiya SM and  Swan J and  Zakrewska JM and  Pirmohamed M.},
  year = {2026},
  journal = {Br J Clin Pharmacol},
  doi = {10.1002/bcp.70559},
  url = {https://doi.org/10.1002/bcp.70559}
}

RIS

TY  - JOUR
TI  - HLA genotype testing for carbamazepine, oxcarbazepine and eslicarbazepine: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI-PGx).
AU  - Galloway L
AU  -  Dello Russo C
AU  -  Bass N
AU  -  Bramon E
AU  -  Cross H
AU  -  Curley N
AU  -  Curran S
AU  -  Davies H
AU  -  De Villiers J
AU  -  Evans W
AU  -  Frank B
AU  -  Groves A
AU  -  Hayward J
AU  -  Higham J
AU  -  Hughes DA
AU  -  Kyaw SS
AU  -  Marson AG
AU  -  McLellan A
AU  -  Mensah S
AU  -  O'Neill F
AU  -  Sargison J
AU  -  Sisodiya SM
AU  -  Swan J
AU  -  Zakrewska JM
AU  -  Pirmohamed M.
PY  - 2026
JO  - Br J Clin Pharmacol
DO  - 10.1002/bcp.70559
UR  - https://doi.org/10.1002/bcp.70559
ER  -

APA

L, G., C, D. R., N, B., E, B., H, C., N, C., S, C., H, D., J, D. V., W, E., B, F., A, G., J, H., J, H., DA, H., SS, K., AG, M., A, M., S, M., F, O., J, S., SM, S., J, S., JM, Z., & M., P. (2026). HLA genotype testing for carbamazepine, oxcarbazepine and eslicarbazepine: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI-PGx).. Br J Clin Pharmacol. https://doi.org/10.1002/bcp.70559

Source records

europe-pmc · retrieved 2026-09-27T04:23:29.405Z